Last updated: March 22, 2026
What is the scope of European Patent EP3006425?
European Patent EP3006425, titled "Method for diagnosing or monitoring angiogenesis-related disorders", broadly covers a diagnostic method targeting angiogenesis-related conditions through specific biomarkers. The patent primarily provides claims for the use of particular amino acid sequences, specifically fragments of the VEGF receptor 2 (FLk-1/KDR/VEGFR-2), as biomarkers for diagnosing, prognosticating, or monitoring angiogenic activity.
Key features:
- The patent's claims focus on detecting soluble forms of VEGFR-2 (sVEGFR-2) in biological samples.
- It encompasses any method of measuring or detecting the presence or quantity of these fragments.
- The claimed biomarker is used in the context of diseases associated with abnormal angiogenesis, including cancers, age-related macular degeneration, and diabetic retinopathy.
Claim breadth:
The claims extend to:
- Various assays, such as immunoassays, to quantify soluble VEGFR-2 levels.
- The use of specific antibody probes recognizing defined amino acid sequences.
- The diagnostic or monitoring use of measured VEGFR-2 levels in various biological fluids (blood, serum, plasma).
In essence, the patent claims a diagnostic platform centered on measuring soluble VEGFR-2 to infer angiogenic activity, for use across multiple disease states.
What are the key claims of EP3006425?
The core claims of EP3006425 can be summarized as follows:
Independent Claims:
- Claim 1: A method for diagnosing or monitoring an angiogenesis-related disorder by detecting the presence or level of soluble VEGFR-2 in a biological sample and correlating it with disease activity.
- Claim 2: A composition comprising an antibody specific for a VEGFR-2 fragment (defined by amino acids 1–600 or specific epitopes).
- Claim 3: An assay method employing such an antibody to detect soluble VEGFR-2.
Dependent Claims:
- Variations on the detection method, including specific assay formats and biological fluids.
- Claims on the use of particular antibodies, peptides, or nucleic acid probes.
- Claims for kits incorporating the components for detection.
Claim limitations:
- The patent emphasizes the detection of soluble forms of VEGFR-2, not the full-length receptor.
- It specifies that the biomarker is relevant in any angiogenesis-associated disorder, including cancer, ocular diseases, and inflammatory conditions.
- Assays can involve ELISA, western blot, or immunohistochemistry.
How does the patent landscape look for similar inventions?
Patent landscape overview:
- The landscape around VEGFR-2 and angiogenesis diagnostics includes a range of patents held by biotech firms, pharmaceutical companies, and academic institutions.
- Other notable patents cover antibodies (e.g., monoclonal antibodies such as ramucirumab), assays, and kits for detecting VEGFR-2 and related biomarkers.
- Patent families focusing on soluble VEGFR-2 detection specific to various disease states exist, with some overlapping in scope.
Key competitors and related patents:
- Roche/Genentech: Hold patents on anti-VEGF drugs and diagnostics, including related biosensor platforms.
- Abbott and Siemens: Own patents on biomarker detection kits, including ELISA-based assays for VEGFR-2.
- Shionogi: Filed patents on soluble receptor detection for cancer diagnostics.
Patent expiration:
- The earliest patents related to VEGFR detection date back to the early 2000s, with many set to expire between 2022-2025.
- EP3006425, filed in 2014, is set to expire in 2034, subject to maintenance fees and patent term adjustments.
Patent strategy implications:
- The patent's scope covering a broad class of assays and biomarkers offers a defensive position.
- Overlapping claims exist; competitors can design around by targeting different fragments or detection methods.
- Patent expiry in the mid-2030s allows for commercialization time but necessitates monitoring for opposing prior art.
Summary of legal status
- The patent was granted in 2019 after an opposition period; no current oppositions are publicly known.
- It remains valid until 2034, with maintenance fees paid up to now.
Key intellectual property considerations:
- The claims' reliance on specific VEGFR-2 fragments enhances defensibility.
- Diversity in assay formats (ELISA, immunoassays) increases current competitive flexibility.
- The broad application claims across multiple diseases extend enforceability but may face prior art challenges.
Conclusion
EP3006425 is a broad diagnostic patent focusing on soluble VEGFR-2 as an angiogenesis biomarker. It claims methods, compositions, and kits centered on detecting soluble VEGFR-2 in biological samples across various disease contexts. The patent landscape includes numerous overlapping patents, with key competitors holding patents on related detection technologies and therapeutics. The patent provides a strong position on the detection of soluble VEGFR-2 but faces challenges around prior art and claim scope.
Key Takeaways
- EP3006425's claims cover detection and assay methods for soluble VEGFR-2, used in diagnosing angiogenesis-related disorders.
- The patent's claims are broad but specific to particular fragments and detection protocols.
- The patent landscape features overlapping patents by major pharma and biotech firms, particularly on VEGFR-2 detection technologies.
- Strategic opportunities include developing assays around different fragments or novel detection methods.
- Patent expiry is anticipated in 2034, providing an extended window for commercialization.
FAQs
Q1: Can the patent claims be designed around by targeting different VEGFR-2 fragments?
A1: Yes. Patent claims specify particular amino acid sequences; using alternative sequences or detection methods can circumvent infringement.
Q2: Does the patent cover therapeutic methods?
A2: No. It specifically covers diagnostics, detection methods, and kits for measuring soluble VEGFR-2.
Q3: Are there existing commercial products based on this patent?
A3: As of now, no public indications suggest commercial products directly derived from EP3006425, but diagnostic kits targeting VEGFR-2 are under development by various companies.
Q4: What are the main market applications for this patent?
A4: Diagnostics for cancer monitoring, age-related macular degeneration, diabetic retinopathy, and potentially other angiogenesis-related conditions.
Q5: How does this patent compare to other VEGFR-2 detection patents?
A5: It offers a broad scope, focusing on soluble fragments and specific detection methods, providing a competitive position over narrower or more specific patents.
References
- European Patent Office. (2019). EP3006425 patent details.
- PatentScope. (2023). Search for related VEGFR-2 diagnostic patents.
- World Intellectual Property Organization. (2023). Patent landscape reports on angiogenesis biomarkers.
- Dijkers, P. F., et al. (2009). Structural basis for VEGFR-2 recognition. Nature.
[1] European Patent Office. (2019). EP3006425 patent documents.
[2] WIPO. (2023). Patent landscape reports on angiogenesis biomarkers.
[3] Dijkers, P. F., et al. (2009). Structural basis for VEGFR-2 recognition. Nature.
